Overview
Monika Richter focuses her practice on the biotechnology and pharmaceuticals sector. She advises national and international clients on various commercial legal matters related to the development, manufacturing and commercialization of medicinal products, with a particular focus on strategic alliances, research and development collaborations, license agreements, commercial manufacturing and supply agreements and distribution agreements. Her work likewise includes financing and corporate transactions as well as mergers and acquisitions.
Given her Polish background, Monika is active in the Eastern European market, regularly speaking at industry conferences in Poland and advising Polish clients on several cross-border collaborations in the life sciences sector.
Results
- Advised Ryvu Therapeutics (formerly named Selvita), one of Poland’s largest biotechnology companies, on an exclusive license agreement with Exelixis and on various other* international licensing and collaboration agreements, including with Orion Pharma, H3, Felicitex, Merck KGaA and Menarini, and on a funding agreement with the Leukemia and Lymphoma Society
- Advised Moffitt Cancer Center, a world leader in advancing cellular immunotherapies for the treatment of cancer, in its strategic alliance with Turnstone Biologics
- Advised Paion on license agreements for development and commercialization of Remimazolam in various territories, e.g. with Cristalia Produtos Quimicos Farmaceuticos (Brazil), Mundipharma (Japan) and TTY (Taiwan), as well as on various distribution agreements and commercial manufacturing and supply agreements regarding Remimazolam and other products
- Advised lifespin GmbH on a research cooperation with Biobank Graz and the Clinical Department of Oncology of the Medical University of Graz
- Advised REGENXBIO on co-development and licensing partnership with AbbVie for development of RGX-314, a potential one-time gene therapy for retinal diseases
- Advised STADA on exclusive licensing transaction with Calliditas for commercialization of novel specialty drug for treatment of chronic autoimmune kidney disease
- Advised Merck on an out-licensing transaction with Diaccurate, on a co-development and licensing partnership with Neuroloop (B. Braun start-up) for the development of neurostimulator device for treatment of chronic inflammatory diseases and on various other collaboration agreements
- Advised Biogen Inc. on various in-licensing collaborations, including with Reborna (Takeda spin-out), Cevec, iSD
- Advised Treeway on out-licensing transaction with Ferrer for development of compound for treatment of ALS and other neurodegenerative diseases
- Advised Adamed on out-licensing transaction with Acadia on early stage compound
- Advised OncoArendi on out-licensing transaction with Galapagos for development of clinical stage candidate for treatment of fibrotic diseases
Recognitions
- Handelsblatt/Best Lawyers 2021, 2022 and 2023 Germany: Leading Lawyer for Biotechnology Law and Life Sciences Practice
- Legal 500 EMEA 2022: “Monika Richter: Forward-looking, prudent, razor-sharp when it comes to implementing client interests.”; „The team around Monika Richter and Deniz Tschammler offers an exceptional combination of industry expertise in the healthcare sector and deal experience.“
- Leaders League’ 2019 Guide, Innovation, Technology & Patents: “Excellent” in the Health, pharma & biotechnology category
